Analyst Michael Grondahl of Northland Securities maintained a Buy rating on Abacus Life, with a price target of $13.50.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Grondahl has given his Buy rating due to a combination of factors that highlight Abacus Life’s strong performance and promising outlook. The company reported a robust second quarter in 2025, with significant increases in revenue, adjusted EBITDA, and adjusted EPS, which exceeded expectations. The growth in origination capital deployment and the number of policies further underscores the company’s solid operational momentum.
Additionally, Abacus Life is benefiting from increased demand for its assets as institutional investors seek less correlated yield opportunities. The company’s strategic initiatives, such as hiring wholesalers for its ETF side and engaging with large pension funds, are expected to drive future growth. Grondahl’s positive outlook is also supported by the company’s introduction of new key performance indicators, which demonstrate improved capital turnover and sales velocity, and the establishment of optimistic revenue and earnings estimates for 2026.